Shares in TFS Corporation were firmer after it said its over-the-counter acne treatment kit would be launched early this year.
The Santalia acne treatment kit is the first in a range of dermatological products TFS hopes to launch through its 50 per cent owned joint venture company Santalis Pharmaceuticals.
The launch of Santalia follows a successful clinical trial of the product which showed it reduced patient lesion counts with minimal side effects.
The product is formulated using sustainably-grown, pharmaceutical-grade East Indian sandalwood oil and is designed to provide anti-bacterial and anti-inflammatory benefits without the drawbacks often associated with benzoyl peroxide-containing products, such as dryness and irritation of the skin.
TFS said the product would be available online and later through private-label distribution partners.
The company also announced the appointment of Dylan Greenway as business development manager for NSW and Simon Storm as joint company secretary.
TFS shares were up two cents, or 5 per cent, to 42 cents at 11.50am.